Jung Hwan Park

Jung Hwan Park

Auto-generated profile, based on publicly available information

Jung Hwan Park

Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
JPJung Hwan Park
Jung Hwan Park
YJYong-Il Jo
Yong-Il Jo
JLJong-Ho Lee
Jong-Ho Lee
The prevalence of chronic kidney disease (CKD) is increasing worldwide. Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function. Recent observational studies of healthy populations and patients with CKD have reported that uric acid (UA) has an independent role in the development or progression of CKD. Experimental studies have shown several potential mechanisms by which hyperuricemia may cause or promote CKD. However, other reports have indicated an association between hypouricemia and CKD. This opposing effect is hypothesized to occur because UA is a major antioxidant in human plasma and is associated with oxidative stress. In this article, we discuss the potential association between UA imbalance and CKD and how they can be treated.

1 July 2018 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
JPJung Hwan Park
Jung Hwan Park
YJYoung-Il Jo
Young-Il Jo
JLJong-Ho Lee
Jong-Ho Lee
Chronic volume overload is associated with left ventricular hypertrophy and high cardiovascular mortality in patients undergoing dialysis. Therefore, estimating body fluid status is important in these patients. However, most dry-weight assessments are still performed clinically, while attempts have been made to measure the volume status and dry weight of patients undergoing dialysis using bioimpedance analysis (BIA). BIA uses the electrical properties of the human body to alternate current flow and measures resistance values to estimate body water content and composition. BIA is divided into single-frequency BIA, multi-frequency BIA, and bioimpedance spectroscopy (BIS) according to the number of frequencies used, and into whole-body and segmental BIA according to whether or not the whole body is divided into segments. Extracellular water (ECW), intracellular water, and total body water (TBW) contents can be measured with BIA. Dry weight can be estimated by measuring the volume overload of the patient through the ECW/TBW and ECW-to-body weight ratios. Other estimation methods include the normovolemia/hypervolemia slope method, a resistance-reactance (RXc) graph, overhydration measurements using a body composition monitor, and calf BIS. In this review, we will examine the principles of BIA, introduce various volume status measurement methods, and identify the optimal method for patients undergoing dialysis.

9 November 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
HCHo Jun Chin
Ho Jun Chin
DCDong-Wan Chae
Dong-Wan Chae
YKYong Chul Kim
Yong Chul Kim
Won Suk AnWon Suk An
Won Suk An
CIChunGyoo Ihm
ChunGyoo Ihm
SLSang Koo Lee
Sang Koo Lee
Significance Statement: Steroid resistance, relapse, and side effects are common issues in use of high-dose steroids as first-line treatment for adult minimal change nephrotic syndrome. Tacrolimus is used as a steroid-sparing immunosuppressant to reduce adverse effects of long-term or repeated steroid treatment, but no large-scale randomized study has compared combined tacrolimus and low-dose steroid with high-dose steroid in treating minimal change nephrotic syndrome in adults. In this open-label randomized trial, the authors found that treatment with tacrolimus plus low-dose steroid was noninferior to high-dose steroid for complete remission at 8 weeks, and that treatment with a maintenance dose of tacrolimus during steroid tapering reduced the relapse rate, with no clinically-relevant safety differences. This indicates that tacrolimus is an effective alternative to high-dose steroids in this disease, although investigation into long-term safety is warranted. Background: Tacrolimus is used as a steroid-sparing immunosuppressant in adults with minimal change nephrotic syndrome. However, combined treatment with tacrolimus and low-dose steroid has not been compared with high-dose steroid for induction of clinical remission in a large-scale randomized study. Methods: In this 24-week open-label noninferiority study, we randomized 144 adults with minimal change nephrotic syndrome to receive 0.05 mg/kg twice-daily tacrolimus plus once-daily 0.5 mg/kg prednisolone, or once-daily 1 mg/kg prednisolone alone, for up to 8 weeks or until achieving complete remission. Two weeks after complete remission, we tapered the steroid to a maintenance dose of 5–7.5 mg/d in both groups until 24 weeks after study drug initiation. The primary end point was complete remission within 8 weeks (urine protein: creatinine ratio 3.0 g/g) after complete remission to within 24 weeks of study drug initiation. Results: Complete remission within 8 weeks occurred in 53 of 67 patients (79.1%) receiving tacrolimus and low-dose steroid and 53 of 69 patients (76.8%) receiving high-dose steroid; this difference demonstrated noninferiority, with an upper confidence limit below the predefined threshold (20%) in both intent-to-treat (11.6%) and per-protocol (17.0%) analyses. Groups did not significantly differ in time until remission. Significantly fewer patients relapsed on maintenance tacrolimus (3–8 ng/ml) plus tapered steroid versus tapered steroid alone (5.7% versus 22.6%, respectively; P=0.01). There were no clinically relevant safety differences. Conclusions: Combined tacrolimus and low-dose steroid was noninferior to high-dose steroid for complete remission induction in adults with minimal change nephrotic syndrome. Relapse rates were significantly lower with maintenance tacrolimus and steroid compared with steroid alone. No clinically-relevant differences in safety findings were observed.

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HKHoseok Koo
Hoseok Koo
YKYong Chul Kim
Yong Chul Kim
SAShin Young Ahn
Shin Young Ahn
SOSe Won Oh
Se Won Oh
SKSuhnggwon Kim
Suhnggwon Kim
JPJung Hwan Park
Jung Hwan Park
Koo HS, et al. J Korean Med Sci. 2014 Sep;29(Suppl 2):S97-S102. https://doi.org/10.3346/jkms.2014.29.S2.S97

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
KKKipyo Kim
Kipyo Kim
SGSuryeong Go
Suryeong Go
HSHyung Eun Son
Hyung Eun Son
JRJi Young Ryu
Ji Young Ryu
HLHajeong Lee
Hajeong Lee
JPJung Hwan Park
Jung Hwan Park
Kim K, et al. J Korean Med Sci. 2020 Jun;35(28):e254. https://doi.org/10.3346/jkms.2020.35.e254

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JPJung Hwan Park
Jung Hwan Park
YKYong Chul Kim
Yong Chul Kim
HKHoseok Koo
Hoseok Koo
SOSewon Oh
Sewon Oh
SKSuhnggwon Kim
Suhnggwon Kim
HCHo Jun Chin
Ho Jun Chin
Park JH, et al. J Korean Med Sci. 2014 Sep;29(Suppl 2):S131-S138. http://dx.doi.org/10.3346/jkms.2014.29.S2.S131